Caligan Partners LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001727492

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 26 positions · Total reported value $1.71B · Top-10 concentration 81.5% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 41.9% · 5 new · 3 cut · 5 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +38.3% · vs SPY +23.5% · Prev Value $1.30B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Caligan Partners LP disclosed 26 equity positions with a combined reported value of $1.71B. The filing implies a focused portfolio: its ten largest positions account for 81.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were LQDA ($647.32M), ABVX ($207.61M), PCVX ($127.23M). By sector, the heaviest allocations are Health Care 99.1%, Other 0.9%. Versus the prior quarter, allocation shifted toward Other (+0.6pp) and away from Health Care (-0.6pp).

Versus the prior quarter, Caligan Partners LP opened 5 new positions, trimmed 3 and fully exited 5, a turnover rate of 41.9% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q2 2026 were IMCR ($43.86M), VRDN ($40.30M), SGMT ($19.32M).

Of the 5 positions fully exited versus the prior quarter, the largest were MLYS ($75.11M), CGON ($60.91M), SYRE ($44.29M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • IMCR IMMUNOCORE HLDGS PLC · $43.86M
  • VRDN VIRIDIAN THERAPEUTICS INC · $40.30M
  • SGMT SAGIMET BIOSCIENCES INC A · $19.32M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · $16.84M
  • CLRB CELLECTAR BIOSCIENCES INC · $1.31M

Fully Exited (vs previous quarter)

  • MLYS MINERALYS THERAPEUTICS INC · prev qtr: $75.11M
  • CGON CG ONCOLOGY INC · prev qtr: $60.91M
  • SYRE SPYRE THERAPEUTICS INC · prev qtr: $44.29M
  • MAZE MAZE THERAPEUTICS INC · prev qtr: $18.36M
  • XLO Xilio Therapeutics Inc. · prev qtr: $943.00K

Insider Transactions (Form 4)

Latest Caligan Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-16 Award Liquidia Corp 5,882 — SEC filing
2026-05-19 Buy Liquidia Corp 5,300 $59.98 SEC filing
2026-05-19 Sell Liquidia Corp 5,300 $59.98 SEC filing

All insider transactions →

Fund Profile

Caligan Partners LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 26 US equity positions with a combined value of $1.71B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-113810 (status: Approved), registered 2018-08-10
  • Regulatory AUM (Form ADV): $1.30B as of 2026-05-29
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: caliganpartners.com

Portfolio Structure

  • 26 positions · $1.71B reported value (Q2 2026)
  • Top 10 holdings = 81.5% of reported value
  • Largest position: LQDA (LIQUIDIA CORPORATION) at 37.8%
  • Average position size: $65.78M

Sector Tilt

  • Health Care 99.1%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 5 new, 8 added, 3 reduced, 5 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Caligan Partners LP appears to be maintaining a cautious approach, with a focus on healthcare sector investments. The slight additions and reductions in holdings suggest a preference for stability and growth within the healthcare sector, possibly indicating a belief in long-term prospects for the industry. 2. Key Moves: - Added: ABVX (ABIVAX SA), PCVX (VAXCYTE INC), TNGX (TANGO THERAPEUTICS INC), AVTX (AVALO THERAPEUTICS INC), RVMD (REVOLUTION MEDICINES INC), and IMCR (IMMUNOCORE HOLDINGS PLC-ADR CO). These additions were significant, particularly AVTX, which saw a 93.5% increase in shares. - Reduced: XENE (XENON PHARMACEUTICALS INC) with a 36.1% decrease in shares. - No Change: LQDA (LIQUIDIA CORPORATION), ABVX, PCVX, EXEL (EXELIXIS INC), TNGX, LBRX (LB PHARMACEUTICALS INC), and IMCR. 3. Portfolio Structure: - Passive/Active: The portfolio seems to be actively managed, as there are clear additions, reductions, and changes in shareholdings. - Sector Bias: The portfolio is heavily biased towards the healthcare sector, with a significant allocation to biotechnology and pharmaceutical companies. - Risk Appetite: The risk appetite appears moderate, with a mix of additions to potentially high-growth companies and reductions in less favored stocks. 4. Per-Holding One-Liner: - LQDA: A biopharmaceutical company focusing on novel therapies. - ABVX: A biopharmaceutical company focused on developing treatments for cancer. - PCVX: A biotechnology company developing treatments for various diseases. - EXEL: A biotechnology company focusing on novel cancer immunotherapies. - TNGX: A biotechnology company focused on developing treatments for cancer and rare diseases. - AVTX: A biotechnology company developing therapies for neurological and rare diseases. - XENE: A biopharmaceutical company focused on developing treatments for cancer. - RVMD: A biopharmaceutical company focused on novel therapies for rare and orphan diseases. - LBRX: A biopharmaceutical company focused on developing treatments for various diseases. - IMCR: A biopharmaceutical company focused on developing therapies for cancer and infectious diseases. ('Unverified' for all, as specific business details were not provided.) 5. One-Sentence Style Summary: Caligan Partners LP's rebalancing this quarter indicates a preference for healthcare sector investments, with a focus on biotechnology and pharmaceutical companies, while maintaining a cautious and actively managed approach.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 99.1%
Other 0.9%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 8.12M $647.32M 37.85%
37.85%
Hold
2 1.56M $207.61M 12.14%
12.14%
Add
3 2.19M $127.23M 7.44%
7.44%
Add
4 1.55M $84.51M 4.94%
4.94%
Hold
5 2.50M $78.15M 4.57%
4.57%
Add
6 3.16M $58.47M 3.42%
3.42%
Add
7 889.94K $53.72M 3.14%
3.14%
Reduce
8 251.80K $47.16M 2.76%
2.76%
Add
9 1.44M $46.67M 2.73%
2.73%
Hold
10 1.38M $43.86M 2.56%
2.56%
New
11 2.19M $40.30M 2.36%
2.36%
New
12 1.93M $35.44M 2.07%
2.07%
Hold
13 7.97M $31.07M 1.82%
1.82%
Hold
14 8.16M $30.86M 1.80%
1.80%
Add
15 4.30M $30.52M 1.78%
1.78%
Add
16 806.99K $25.78M 1.51%
1.51%
Reduce
17 6.08M $24.98M 1.46%
1.46%
Hold
18 1.44M $21.00M 1.23%
1.23%
Hold
19 2.50M $19.32M 1.13%
1.13%
New
20 1.74M $16.84M 0.98%
0.98%
New
21 629.47K $15.74M 0.92%
0.92%
Add
22 200.00K $11.04M 0.65%
0.65%
Reduce
23 923.91K $5.65M 0.33%
0.33%
Hold
24 90.00K $3.34M 0.20%
0.20%
Hold
25 300.00K $2.51M 0.15%
0.15%
Hold
26 470.00K $1.31M 0.08%
0.08%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 60% R 60% F1 60% (modelled on 2026-Q1; 6/10 hit)

Low-confidence forecast This fund replaces about 21% of its Top-10 each quarter and backtests at F1 79% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 79% · recall 79% · F1 79% · avg rank error 2.0 · Top-10 turnover 21%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 80% 80% 80% LQDA · ALIM · ANIK · EXEL · LAB · EOLS · AGIO · YMAB · VRNA · ADMA LQDA · ALIM · ANIK · EOLS · EXEL · VRNA · ENTA · AGIO · YMAB · OTLK
2024-Q2 80% 80% 80% LQDA · ALIM · ANIK · EOLS · EXEL · VRNA · AGIO · ENTA · YMAB · OTLK LQDA · ALIM · ANIK · EXEL · BCRX · VRNA · EOLS · AGIO · ENTA · MLYS
2024-Q3 80% 80% 80% LQDA · ALIM · ANIK · EXEL · BCRX · VRNA · EOLS · AGIO · ENTA · MLYS LQDA · VRNA · EXEL · EOLS · ANIK · AGIO · BCRX · YMAB · MLYS · NBP
2024-Q4 90% 90% 90% LQDA · VRNA · EXEL · EOLS · ANIK · AGIO · BCRX · YMAB · MLYS · NBP LQDA · VRNA · EXEL · EOLS · ANIK · BCRX · AGIO · SAGE · YMAB · MLYS
2025-Q1 90% 90% 90% LQDA · VRNA · EXEL · EOLS · ANIK · BCRX · AGIO · SAGE · YMAB · MLYS LQDA · VRNA · EXEL · MLYS · EOLS · SAGE · BCRX · ANIK · AGIO · RVMD
2025-Q2 80% 80% 80% LQDA · VRNA · EXEL · MLYS · EOLS · SAGE · BCRX · ANIK · AGIO · MRUS VRNA · LQDA · EXEL · AGIO · MRUS · EOLS · MLYS · RVMD · ANIK · ABVX
2025-Q3 80% 80% 80% VRNA · LQDA · EXEL · MRUS · AGIO · EOLS · MLYS · RVMD · ANIK · ABVX LQDA · ABVX · MLYS · EXEL · RVMD · AGIO · ADMA · EOLS · MRUS · XENE
2025-Q4 70% 70% 70% LQDA · ABVX · MLYS · EXEL · RVMD · ADMA · AGIO · EOLS · MRUS · XENE LQDA · ABVX · RVMD · MLYS · PCVX · EXEL · ADMA · TNGX · TYRA · XENE
2026-Q1 80% 80% 80% LQDA · ABVX · RVMD · MLYS · PCVX · EXEL · ADMA · TNGX · TYRA · XENE LQDA · ABVX · PCVX · XENE · MLYS · EXEL · CGON · TNGX · TYRA · SYRE
2026-Q2 ★ 60% 60% 60% LQDA · ABVX · PCVX · XENE · MLYS · EXEL · CGON · TYRA · TNGX · SYRE LQDA · ABVX · PCVX · EXEL · TNGX · AVTX · XENE · RVMD · LBRX · IMCR

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Caligan Partners LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Caligan Partners LP reported 26 equity positions worth $1.71B in aggregate; its largest disclosed positions were LQDA ($647.32M), ABVX ($207.61M), PCVX ($127.23M).

How large is Caligan Partners LP's portfolio?

Caligan Partners LP reported $1.71B of long equity holdings across 26 positions as of 2026-Q2. Top-10 holdings account for 81.5% of reported value.

What is Caligan Partners LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/caligan-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →